<p>Tilray（納斯達克代碼：TLRY - 獲取免費報告）預計將在 4 月 8 日星期二市場開盤前公佈其財報。分析師預計該公司本季度每股收益為（$0.04），收入為 2.1338 億美元。Tilray 已將其 2025 財年的指引設定為每股收益。</p>
<ul>
<li>尋求穩定？這三隻股票提供強勁潛力</li>
</ul>
<p>Tilray（納斯達克代碼：TLRY - 獲取免費報告）上一次公佈財報是在 1 月 10 日星期五。該公司報告本季度每股收益為（$0.10），低於分析師一致預期的（$0.03），差距為（$0.07）。該公司本季度的收入為 2.109 億美元，而分析師預期為 2.1634 億美元。Tilray 的淨利潤率為負 30.95%，股本回報率為負 4.40%。與去年同期相比，該公司的季度收入增長了 8.7%。分析師平均預計 Tilray 在當前財年的每股收益為$0，在下一個財年的每股收益也為$0。</p>
<h2>Tilray 股價下跌 0.8%</h2>
<p>TLRY 股票在星期二開盤時為$0.66。該公司的 50 日移動平均為$0.84，200 日移動平均為$1.25。該公司的市值為 6.1651 億美元，市盈率為-2.19，貝塔值為 2.13。Tilray 的 1 年最低價為$0.58，最高價為$2.97。該公司的債務與股本比率為 0.10，流動比率為 2.54，速動比率為 1.58。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>大麻股票：該行業的變革性催化劑？</li>
</ul>
<p>另外，Canaccord Genuity Group 在 1 月 13 日星期一的報告中將 Tilray 的目標價從$2.00 上調至$3.00，並給予該公司 “買入” 評級。三位投資分析師對該股票給予持有評級，兩位分析師給予買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “持有”，共識目標價為$2.70。</p>
<p><strong>閲讀我們最新的 TLRY 股票分析</strong></p>
<h2>Tilray 公司簡介</h2>
<p>（獲取免費報告）</p>
<ul>
<li>Tilray 的第三季度財報顯示儘管面臨挑戰仍有增長</li>
</ul>
<p>Tilray, Inc 從事醫療大麻的研究、種植、加工和分銷。該公司的產品在阿根廷、澳大利亞、加拿大、智利、克羅地亞、塞浦路斯、捷克共和國、德國、新西蘭和南非銷售。Tilray, Inc 總部位於加拿大。</p>
<h2>閲讀更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Tilray</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>三隻可買入的股票，底部堅實，準備反彈</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>Advantage+ 購物：Meta 快速增長的 200 億美元 AI 廣告明星</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>Robotaxi 新聞：特斯拉和 Lyft 的頭條對股票的影響</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VExSWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VExSWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Tilray 嗎？</h2>
<p>在你考慮 Tilray 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Tilray 並不在名單上。</p>
<p>雖然 Tilray 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TLRY

<p>Tilray（納斯達克代碼：TLRY）將於 4 月 8 日公佈季度財報，分析師預計每股虧損 0.04 美元，收入為 2.1338 億美元。該公司此前報告每股虧損 0.10 美元，未能達到預期。Tilray 的股票目前交易價格為 0.66 美元，市值為 6.1651 億美元。分析師對 Tilray 的共識評級為 “持有”，目標價格為 2.70 美元。Canaccord Genuity 最近將其目標價格從 2.00 美元上調至 3.00 美元，並維持 “買入” 評級</p>

<p>Tilray (NASDAQ:TLRY - Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $213.38 million for the quarter. Tilray has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Tilray（納斯達克代碼：TLRY - 獲取免費報告）預計將在 4 月 8 日星期二市場開盤前公佈其財報。分析師預計該公司本季度每股收益為（$0.04），收入為 2.1338 億美元。Tilray 已將其 2025 財年的指引設定為每股收益。</p>
</div><ul>
<li>Seeking Stability? These 3 Stocks Offer Strong Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>尋求穩定？這三隻股票提供強勁潛力</li>
</ul>
</div><p>Tilray (NASDAQ:TLRY - Get Free Report) last posted its earnings results on Friday, January 10th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.07). The company had revenue of $210.90 million during the quarter, compared to analyst estimates of $216.34 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The firm's quarterly revenue was up 8.7% compared to the same quarter last year. On average, analysts expect Tilray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Tilray（納斯達克代碼：TLRY - 獲取免費報告）上一次公佈財報是在 1 月 10 日星期五。該公司報告本季度每股收益為（$0.10），低於分析師一致預期的（$0.03），差距為（$0.07）。該公司本季度的收入為 2.109 億美元，而分析師預期為 2.1634 億美元。Tilray 的淨利潤率為負 30.95%，股本回報率為負 4.40%。與去年同期相比，該公司的季度收入增長了 8.7%。分析師平均預計 Tilray 在當前財年的每股收益為$0，在下一個財年的每股收益也為$0。</p>
</div><h2>Tilray Trading Down 0.8 %</h2>
<div class="lb-trans"><h2>Tilray 股價下跌 0.8%</h2>
</div><p>Shares of TLRY stock opened at $0.66 on Tuesday. The company has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.25. The firm has a market cap of $616.51 million, a PE ratio of -2.19 and a beta of 2.13. Tilray has a 1-year low of $0.58 and a 1-year high of $2.97. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58.</p>
<div class="lb-trans"><p>TLRY 股票在星期二開盤時為$0.66。該公司的 50 日移動平均為$0.84，200 日移動平均為$1.25。該公司的市值為 6.1651 億美元，市盈率為-2.19，貝塔值為 2.13。Tilray 的 1 年最低價為$0.58，最高價為$2.97。該公司的債務與股本比率為 0.10，流動比率為 2.54，速動比率為 1.58。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>Cannabis Stocks: Game-Changing Catalyst for the Sector?</li>
</ul>
<div class="lb-trans"><ul>
<li>大麻股票：該行業的變革性催化劑？</li>
</ul>
</div><p>Separately, Canaccord Genuity Group lifted their target price on shares of Tilray from $2.00 to $3.00 and gave the company a &#34;buy&#34; rating in a report on Monday, January 13th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $2.70.</p>
<div class="lb-trans"><p>另外，Canaccord Genuity Group 在 1 月 13 日星期一的報告中將 Tilray 的目標價從$2.00 上調至$3.00，並給予該公司 “買入” 評級。三位投資分析師對該股票給予持有評級，兩位分析師給予買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “持有”，共識目標價為$2.70。</p>
</div><p><strong>Read Our Latest Stock Analysis on TLRY</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 TLRY 股票分析</strong></p>
</div><h2>Tilray Company Profile</h2>
<div class="lb-trans"><h2>Tilray 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>Tilray’s Q3 Earnings Reveal Growth Despite Challenges</li>
</ul>
<div class="lb-trans"><ul>
<li>Tilray 的第三季度財報顯示儘管面臨挑戰仍有增長</li>
</ul>
</div><p>Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.</p>
<div class="lb-trans"><p>Tilray, Inc 從事醫療大麻的研究、種植、加工和分銷。該公司的產品在阿根廷、澳大利亞、加拿大、智利、克羅地亞、塞浦路斯、捷克共和國、德國、新西蘭和南非銷售。Tilray, Inc 總部位於加拿大。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Tilray</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>3 Buyable Stocks With Solid Bottoms Ready to Rebound</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Advantage+ Shopping: Meta's Fast Growing $20 Billion AI-Ads Star</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Robotaxi News: What Tesla and Lyft Headlines Mean for Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Tilray</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>三隻可買入的股票，底部堅實，準備反彈</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>Advantage+ 購物：Meta 快速增長的 200 億美元 AI 廣告明星</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>Robotaxi 新聞：特斯拉和 Lyft 的頭條對股票的影響</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VExSWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TLRY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tilray Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Tilray 嗎？</h2>
</div><p>Before you consider Tilray, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Tilray 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Tilray 並不在名單上。</p>
</div><p>While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tilray 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tilray Brands (TLRY) 預計將在週二公佈季度財報